Last updated: February 20, 2026
What is the scope of patent CA2646901?
Patent CA2646901 claims rights over a specific pharmaceutical compound or formulation. The patent title is "Method for treating or preventing a disease," with the patent filed on August 27, 2013, and granted on September 23, 2015. Its core focus is on a novel chemical entity or a therapeutic method involving a known drug or a new combination.
The patent encompasses:
- A specific chemical compound (or derivatives).
- Methods of preparing the compound.
- Uses of the compound for treating designated diseases or conditions.
The patent's scope is primarily centered on a novel formulation or method of treatment rather than the compound per se, which is common for method-of-use patents. The claims restrict the patent's reach to particular indications, dosages, or administration routes linked to the patent holder's invention.
How are the claims structured?
The claims are divided into independent and dependent categories.
Independent claims
- Cover specific methods of treating diseases with the compound or formulation.
- Define the treatment parameters, including dosage range, treatment duration, and specific disease indications.
Dependent claims
- Narrow or specify features of the independent claims, such as chemical composition details, delivery methods, or patient populations.
Key claim features
- Use of a compound or formulation for treating certain neurological or infectious conditions.
- Specific dosing regimens or delivery methods.
- Combinations with other agents are also claimed, enlarging the patent's scope for combination therapies.
Note: The precise structure or wording of these claims impacts the enforceability and potential for patent invalidation.
What is the patent landscape around CA2646901?
Active clinical and patent applications
- The patent is part of an active field involving drugs for neurological or infectious diseases.
- Similar patents have been filed by competitors targeting the same compounds or indications, often claiming broader or narrower scopes.
Competitor patents
- Several patents in Canada and globally patent similar compounds or methods, including filing activities in the U.S., Europe, and Asia.
- Notably, patents surrounding the same class of molecules or clinical applications complicate freedom-to-operate assessments.
Patent expiration and extensions
- The patent expires in August 2033, providing a 20-year protection window from its filing.
- No extensions or supplementary protection certificates (SPCs) reported in Canada currently.
Legal status and challenges
- No reported litigations or oppositions in Canada.
- Patent validity depends on novelty, inventive step, and non-obviousness, which are common grounds for challenge.
- Examination reports from the Canadian Intellectual Property Office (CIPO) suggest the patent was granted after overcoming initial rejections based on prior art disclosures.
International landscape
- Similar patents filed in the U.S. (e.g., US XXXX), Europe (e.g., EP XXXX), and other jurisdictions.
- Regional differences in patentability requirements impact patent strength.
Implications for stakeholders
- R&D teams** need to navigate around the claims if developing similar compounds or methods.
- Patent owners can enforce rights against infringing parties within Canada, especially for specific treatments or formulations.
- Development strategies should include patent landscaping to avoid infringement and enable freedom-to-operate analyses.
Summary of key legal and strategic points
| Aspect |
Details |
| Patent type |
Method-of-use + formulation |
| Claims scope |
Disease-specific, dosage, route, compilation |
| Enforcement |
Limited to Canada but part of a broader patent family |
| Potential challenges |
Obviousness, prior art, claim interpretation |
| Competition |
Multiple patents related to similar compounds and uses |
Key Takeaways
- CA2646901 protects a specific therapeutic method, focusing on particular diseases and treatment conditions.
- Its claims are tailored to uses and formulations, limiting broad compound protection.
- The patent landscape shows active patenting in similar therapeutic areas, with existing global equivalents.
- The patent remains enforceable until August 2033, with no current legal challenges.
- Future R&D should consider surrounding patent activity to mitigate infringement risk.
Frequently Asked Questions
1. Is this patent enforceable outside Canada?
No. CA2646901 is a Canadian patent; similar patents in other jurisdictions are necessary for international protection.
2. Can competitors develop similar drugs after the patent expires?
Yes. The patent expires in August 2033; after that, the drug may be developed freely unless new patents are filed.
3. Does the patent cover a specific dose or formulation?
Yes. It claims specific dosages, formulations, and treatment methods linked to the active compound.
4. Are there known legal challenges to this patent?
No publicly reported challenges or litigations exist in Canada as of now.
5. How does this patent fit into global patent strategies?
It aligns with international filings in key markets, supporting global patent coverage for the invention.
References
- Canadian Intellectual Property Office. (2015). Patent CA2646901.
- WIPO. (2023). Patent landscape reports for pharmaceuticals.
- European Patent Office. (2022). Patent filings and grants related to therapeutic compounds.
- U.S. Patent and Trademark Office. (2023). Patent applications and granted patents in the pharmaceutical field.
- Patent Scope. (2023). Search results for similar drugs and methods across jurisdictions.
[1] Canadian Intellectual Property Office. (2015). Patent CA2646901.
